Publikationen in Zusammenarbeit mit Forschern von Sahlgrenska University Hospital (12)

2024

  1. Dual disorder: does expert clinical experience support the rationale for cariprazine use?

    European Review for Medical and Pharmacological Sciences, Vol. 28, Núm. 5, pp. 2095-2106

  2. Hematopoietic stem cell transplantation for pediatric patients with non-anaplastic peripheral T-cell lymphoma. An EBMT pediatric diseases working party study

    Bone Marrow Transplantation, Vol. 59, Núm. 5, pp. 604-614

2023

  1. Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study

    HemaSphere, Vol. 7, Núm. 9, pp. E942

2021

  1. Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome

    Leukemia, Vol. 35, Núm. 6, pp. 1745-1750

2020

  1. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

    Blood Cancer Journal, Vol. 10, Núm. 10

  2. The Impact of CHA2DS2-VASc and HAS-BLED Scores on Clinical Outcomes in the Amplatzer Amulet Study

    JACC: Cardiovascular Interventions, Vol. 13, Núm. 18, pp. 2099-2108

  3. Value of FEops HEARTguide patient-specific computational simulations in the planning of left atrial appendage closure with the Amplatzer Amulet closure device: Rationale and design of the PREDICT-LAA study

    Open Heart, Vol. 7, Núm. 2

2018

  1. Prevention and management of adverse events of novel agents in multiple myeloma: A consensus of the European Myeloma Network

    Leukemia, Vol. 32, Núm. 7, pp. 1542-1560

2017

  1. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study

    Leukemia, Vol. 31, Núm. 11, pp. 2443-2448

  2. Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the European myeloma network

    Leukemia, Vol. 2017

2016

  1. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

2014

  1. New drugs and novel mechanisms of action in multiple myeloma in 2013: A report from the International Myeloma Working Group (IMWG)

    Leukemia, Vol. 28, Núm. 3, pp. 525-542